Abstract Schwannomas may develop sporadically or in association with NF2 and schwannomatosis. The fundamental aberration in schwannomas is the biallelic inactivation of the NF2 gene. However, clinical and molecular data suggest that these tumors share a common pathogenetic mechanism related to as yet undefined 22q-loci. Linkage studies in schwannomatosis, a condition related to NF2, have defined a candidate 22q-locus and excluded the NF2 gene as the causative germline mutation. Thus, analysis of aberrations in schwannomas may lead to the identification of putative gene(s) involved in the development of schwannoma/schwannomatosis. We profiled a series of 88 schwannomas and constitutional DNA using a tiling path chromosome 22 array. Array-CGH is a suitable method for high-resolution discrimination between germline and tumor-specific aberrations. Previously reported frequencies of 22q-associated deletions in schwannomas display large discrepancies, ranging from 30% to 80%. We detected heterozygous deletions in 53% of schwannomas and the predominant pattern was monosomy 22. In addition, three tumors displayed terminal deletions and four harbored overlapping interstitial deletions of various sizes encompassing the NF2 gene. When profiling constitutional DNA, we identified eight loci that were affected by copy number variation (CNV). Some of the identified CNVs may not be phenotypically neutral and the possible role of these CNVs in the pathogenesis of schwannomas should be studied further. We observed a correlation between the breakpoint position, present in tumor and/or constitutional DNA and the location of segmental duplications. This association implicates these unstable regions in rearrangements occurring both in meiosis and mitosis.
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Introduction
Schwannomas are benign tumors arising from Schwann cells that form the myelin sheaths surrounding the nerve axons. They may develop at various locations in the body, sporadically or in association with neurofibromatosis type 2 (NF2) and schwannomatosis. A large group of schwannomas affect the VIIIth cranial nerve, but can also occur on other cranial, spinal and peripheral nerves. Approximately 95% of VIIIth cranial nerve schwannomas develop as solitary sporadic tumors that occur unilaterally (Antinheimo et al. 1995) . The remaining 5% occur in the context of NF2, a heritable tumor syndrome with a clinical hallmark of bilateral schwannoma, that arise predominantly from the vestibular branch of the VIIIth cranial nerve. NF2 patients are also predisposed to schwannomas in other locations and to other nervous system tumors such as meningiomas and ependymomas (Evans et al. 1992; Parry et al. 1994; Mautner et al. 1996) . The NF2 tumor suppressor gene was characterized from 22q12 and encodes a protein (merlin or schwannomin) that is predominantly located in membrane ruffles and cellular protrusions (Rouleau et al. 1993; Trofatter et al. 1993) . Merlin/schwannomin binds to the cytoskeleton and associates with cell surface glycoproteins. Inactivation of both NF2 alleles, either somatically in sporadic or schwannomatosis-associated schwannomas, or by a combination of germline and somatic NF2 gene mutations in NF2-associated schwannomas, is the fundamental genetic aberration detected in schwannomas. Previous independent analysis of both sporadic, NF2- (Bruder et al. 1999b ) and schwannomatosis-associated schwannomas (Jacoby et al. 1997) have, however, suggested that additional locus/loci from 22q might be involved in schwannoma tumorigenesis. Schwannomatosis has been described as a clinically distinct form of neurofibromatosis, although closely related to NF2 . Moreover, recent linkage analysis in schwannomatosis families have also excluded the NF2 gene mutations as the germline event and defined a separate schwannomatosis-related locus, near the marker D22S1174 (Fig. 1a) , with a maximum LOD score of 6.6 (MacCollin et al. 2003) . In this context, studies of schwannomas, both sporadic as well as associated with schwannomatosis and NF2, should be considered a way to identify a putative schwannomatosis gene.
Previously reported frequencies of 22q-associated deletions in schwannomas display large discrepancies, ranging from 30% to 80% (Seizinger et al. 1986; Bijlsma et al. 1992; Jacoby et al. 1996; Bruder et al. 1999b; Antinheimo et al. 2000) and the NF2 gene is so far the only characterized tumor suppressor gene, involved in the pathogenesis of these tumors. Array-based comparative genomic hybridization (array-CGH) is an efficient and reliable method for analyzing DNA copy number losses and gains in a single experiment (Solinas-Toldo et al. 1997; Pinkel et al. 1998; Snijders et al. 2001; Mantripragada et al. 2004) . In this study, we used a fullcoverage tiling path chromosome 22 array covering 34.7 Mb (Buckley et al. 2002) and applied it to profile a large series of schwannomas and the corresponding normal tissue. The rationale of this study was to determine whether common regions of loss or gain on this chromosome, in either constitutional or tumor-derived tissue could indicate a position of putative gene(s) involved in the development of schwannoma.
Materials and methods

Clinical material
Tumor tissue was sampled during operation and stored between À80°C and À135°C prior to DNA isolation. Fig. 1 Array-CGH profiles of four schwannomas displaying terminal or interstitial deletions. The array contains a maximum number of 460 chromosome 22 measurement points, which are displayed on the X-axis from centromere (left) to telomere (right). Controls derived from chromosome X are plotted between the vertical lines and controls from autosomes other than chromosome 22 are plotted to the right of the chromosome X controls. The Yaxis denotes the value of normalized fluorescence ratio as an average between at least two replicas of each feature on the array. The n-value represents the number of positively scored chromosome 22-derived measurement points from a single experiment. a Schematic drawing of selected chromosome 22 loci/genes. b Detection of a 29.1 Mb telomeric deletion in case S-427 with the breakpoint located in clone AP000555 on the centromeric side of the IGLV/IGLC locus. Chromosome 22 clones scored as deleted exhibit a fluorescence ratio similar to the chromosome X controls (Average Normalized Inter-Locus Fluorescence Ratio (ANILFR) 0.71±SD 0.06 and 0.67±SD 0.07, respectively). The two circles highlights CCNV1, represented by a heterozygous deletion of the first two clones of the array and CCNV4, a homozygous deletion of a single clone (Z84718), harboring DDT, GSTT2, and GSTT1 genes. c An 8.6 Mb tumor-specific interstitial deletion detected in male case S-617 spanning from clone AL022332 to Z68324, including the NF2 locus. Chromosome 22 clones scored as deleted exhibit a fluorescence ratio similar to the chromosome X controls (ANILFR 0.71±SD 0.05 and ANILFR 0.64±SD 0.08). A heterozygous deletion of CCNV2 locus, including clones AC008079 to AC008103 is highlighted with a circle. d A 5.2 Mb tumor-specific interstitial deletion detected in male case S-631 spanning from clone AL035397 to AL008630, also including the NF2 locus. Chromosome 22 clones scored as deleted exhibit a fluorescence ratio similar to the chromosome X controls (ANILFR 0.65 ± SD 0.05 and ANILFR 0.64±SD 0.05). The circle highlights CCNV1 which displays a fluorescence ratio consistent with haploid level. e Detection of a 540 kb deletion encompassing five clones in the NF2 locus, AC000041, AC000035, AC000025, AC005527 and AC005529 (normalized fluorescence ratio 0.72; 0.82; 0.63; 0.69; and 0.82) including NF2 gene, in schwannoma S-814 derived from a female NF2 case. The two circles indicate a regional gain of CCNV1 locus, consistent with three gene copies and a heterozygous deletion of CCNV2 locus. f Schematic representation of clones and genes affected by deletion in S-814. The scale denotes the position on the chromosome according to NCBI (Homo sapiens Genome, build 35.1). Clones are drawn as empty boxes and genes as thick lines. Genes drawn above the axis are transcribed in the plus orientation and those beneath, in the reverse direction c Matched samples of peripheral blood were also collected. High molecular weight DNA was isolated from both tumor and peripheral blood using standard methods. The use of DNA from human subjects has been approved by the local Research Ethics Committee, Faculty of Medicine, Uppsala University (No. 00-087).
Chromosome 22 genomic microarray
The chromosome 22 array covers the entire long arm of the chromosome, with genomic DNA clones derived from the minimal tiling path, without gaps larger than 100 kb, providing long-range coverage, 34.7 Mb and an average resolution of 75 kb (Buckley et al. 2002) . It contains a set of 460 clones derived from chromosome 22, together with chromosome X clones and clones from other autosomes. The average ratio from the nonchromosome 22 autosomal controls was used in the normalization of all array-CGH experiments. A complete list of the set of clones included in the array can be found at http://puffer.genpat.uu.se/chrom_22_array/ chrom22.htm. Each batch of printed slides was validated using DNA derived from a male NF2 patient with a severe phenotype, presenting with a 7.4 Mb constitutional deletion on chromosome 22. The deletion was previously identified by cytogenetics and confirmed by restriction fragment length polymorphism and simple sequence repeat polymorphism analysis as well as by FISH (Bruder et al. 1999a; Buckley et al. 2002) . DNA labeling, hybridization and post-hybridization processing, scanning and image analysis were performed as previously described (Buckley et al. 2002) . A pool of blood-derived DNA from 10 normal females was used as normal control for all performed hybridizations. The Average Normalized Inter-Locus Fluorescence Ratio (ANILFR) was calculated as the average of normalized fluorescence ratios for the clones included within the region presenting genomic imbalance.
Results
Chromosome 22 gene copy number profiling of schwannomas: tumor-specific and disease-associated deletions encompassing the NF2 locus
We have used array-CGH to profile a series of schwannomas, in order to determine possible novel regions of tumor-specific loss or gain that may serve as secondary genetic alterations in this type of tumor, in addition to NF2 gene mutations. We performed gene copy number profiling of 88 schwannoma samples, 84 sporadic and four from patients with a family history of NF2. Fifty-six of the studied schwannomas were derived from the VIIIth cranial nerve, four of which were NF2 associated. The clinical details of patients presenting genetic alterations detected in the course of this study are summarized in Table 1 . We identified heterozygous deletions encompassing the NF2 locus in 47 out of 88 cases (53%). The deletion patterns observed in the tumors can be broadly summarized into three types. The predominant profile was a continuous deletion encompassing all measurement points on 22q, which is consistent with monosomy 22. This profile was observed in 40 out of 47 deletion cases (Table 1 , array-CGH profiles not shown). In the majority of samples presenting monosomy, the level of fluorescence ratio for chromosome 22-derived measurement points was comparable to the level of fluorescence ratio for chromosome X controls, which function as an internal standard for single copy level in male-derived tumors. A similar profile also suggesting a continuous heterozygous deletion, consistent with monosomy 22, was found in four of these 40 cases (S-441, S-455, S-466, and S-499) ( Table 1 , array-CGH profiles not shown). However, the level of fluorescence ratio for chromosome 22 clones scored as deleted in these male cases was consistently higher than the level of chromosome X controls. The presence of a combination of tumor and normal stromal cells or mixed tumor cell populations with different genetic profiles, is the likely reason for the shift in the fluorescence ratios.
The second pattern of aberrations found were 22q terminal deletions, represented by case S-427 in Fig. 1b . Three out of 88 analyzed tumors could be placed into this category, S-9, S-427, and S-500 (Table 1) . These large terminal deletions were all of approximately the same size: 28.9, 29.1, and 30.4 Mb, with the centromeric breakpoint mapping to 22q11.2. We analyzed peripheral blood DNA from these three patients and verified that the genomic imbalances were tumor specific. The third pattern of aberrations detected were interstitial deletions of various sizes, encompassing the NF2 locus. Four cases fall into this category: S-521, S-617, S-631 and S-814 (Table 1 and Fig. 1c-e) , which were 5.0, 8.6, 5.2 and 0.37 Mb in size, respectively. Array-CGH profiling of the corresponding constitutional DNA of these four patients, revealed that all but the smallest deletion were tumor specific. This smallest deletion was found in S-814, a vestibular schwannoma from an NF2 patient, encompassing only five clones (AC000041, AC000035, AC000025, AC005527, and AC005529). Genes affected by the deletion were RFPL1, NEFH, FMIP (also referred in the databases as C22orf19), NIPSNAP1, NF2, LOC400923, CABP7, LOC55954, and HSPC051 (Fig. 1f) . We therefore conclude that this constitutional deletion is the mutation that predisposes this patient to NF2.
Copy number variation outside the NF2 locus in constitutional DNA of patients affected with schwannoma
In the course of the study we identified eight different loci across chromosome 22 affected by DNA copy number variations (CNV) that did not overlap with the NF2 locus. Seven of these CNVs were confirmed to be of germline origin (see below as well as Fig. 2 and Table 1 ). Four of the discovered alterations occurred only once in four different individuals and are therefore referred to as Rare Copy Number Variation (RCNV). The remaining four variations were observed in more than one individual and were therefore named Common Copy Number Variation (CCNV). The array CGH profiles of the samples with RCNVs, highlighted with boxes, are illustrated in Fig. 2 . RCNV1, a regional gain of approximately 280 kb, consistent with three gene copies, was detected in case S-475. The alteration affected nine consecutive clones (D87012-D86996) mapping to the centromeric half of the immunoglobulin lambda variable (IGLV) gene cluster (Fig. 2a, b) . RCNV2 represented a heterozygous deletion of approximately 210 kb, which was identified in schwannoma S-473. This deletion encompassed six clones (D86994-D87024) located in the telomeric end of the IGL locus (Fig. 2c, d ). In this single case, no blood was available from this patient, so the presence of the deletion in constitutional DNA could not be verified. We assume that this variation is of germline origin, as we have identified a deletion encompassing this locus, in constitutional peripheral blood-derived DNA of a patient affected with sporadic schwannomatosis (Buckley et al., manuscript in preparation) . The telomeric breakpoints of the IGL rearrangements in tumor S-473 and schwannomatosis patient overlapped exactly with the position of IGLjoining and IGL-constant gene clusters. On the centromeric side, the breakpoints were different but restricted to the cluster of IGL-variable gene segments. Such a breakpoint distribution is highly similar to the normal IGL locus rearrangements observed in B-lymphocytes. This recombination is a physiological process, mediated by the action of RAG1 and RAG2 enzymes that lead to antibody production in the recombining cell. It should be mentioned that DNA derived from peripheral blood was used as test as well as control samples during hybridizations. B-lymphocytes account for approximately 20% of the total nucleated cell fraction of whole blood. Even if all B-lymphocytes of the patient would have recombined one IGL allele, this could not be detected by array-CGH. Thus, the normal recombination in B-lymphocytes cannot account for the copy number variations found at IGL locus. RCNV3 was detected in S-536; this alteration included three clones (AL022332, AL022324, and AL008721) and was approximately 290 kb in size (Fig. 2e, f) . This region is currently annotated as containing only pseudogenes and putative genes (http:// www.ncbi.nlm.nih.gov/). This 22q region is known to contain segmental duplications (Bailey et al. 2002 ) and this RCNV is therefore likely caused by unequal crossing-over between the duplicated modules. Finally, RCNV4, a 50-75 kb regional gain affecting two cosmids (Z82179 and Z73421) was identified in case S-496. The normalized fluorescence ratio for these clones was 1.44 and 1.35, respectively, indicating three gene copies of this locus, which map to intron 7 of the LARGE gene (Fig. 2g, h ). This gene is one of the largest in the human genome and encodes a member of the N-acetylglucosaminyltransferase gene family (Peyrard et al. 1999; Kanagawa et al. 2004) .
CCNVs 1 through 4, identified in multiple individuals, are listed in Table 1 and indicated by circles in Figs. 1 and 2. CCNV1 involved either loss or gain of about 50 kb, encompassing two consecutives clones on the array (AP000525-AP000526), which map to the pericentromeric region of chromosome 22. This CNV was observed in 22 out of 88 cases (25%), 13 of which were deletions and nine of which were gains (Table 1 and Figs. 1, 2) . CCNV2 encompassing approximately 340 kb (AC008079-AC008103), mapped to the centromeric border of the DiGeorge syndrome critical region 6 (DGCR6) on 22q11. Seventeen deletions (19%) were observed at this locus, which encompassed several known genes: PEX26, TUBA8, USP18, DGCR60, and PRODH (Table 1 and Figs. 1, 2) . CCNV3 which encompassed two consecutive clones on the array (D86991-D87002) was approximately 40 kb in size and mapped to the IGLV region. Nine cases (10%) were found containing deletions at this locus (Table 1 and Fig. 2 ). CCNV4 encompassing a single clone (Z84718) of approximately 100 kb in size, was found deleted in nine cases (Table 1 and Fig. 1 ). Three known genes map to this region: DDT, GSTT2, and GSTT1. Bioinformatic analysis of the genomic sequence in this region revealed the presence of several intrachromosomal segmental duplications (database of segmental duplications at Sequence modules larger than 9,000 bp and with similarity greater than 90% are shown in Fig. 3 . We assume that intra-chromatid recombination between duplicated modules is the likely mechanism behind the altered gene dosage observed for this region.
We further applied our chromosome 22 array to profile a series of peripheral blood derived DNA from 18 phenotypically normal individuals. Four cases (two deletions and two gains) were detected encompassing CCNV1, four cases (four gains) at CCNV2 locus, three cases (one deletion and two gains) at CCNV3 locus, and 1 deletion at CCNV4 locus. It is worth mentioning that all common copy number variations identified in schwannoma patients, except CCNV1, were deletions, while gains were common in controls. Specifically 17 deletion cases (19%) were observed among schwannoma patients at the CCNV2 locus, while only gains, four cases (22%), were discovered in the normal controls. No DNA copy number alterations were identified in these individuals in loci involving RCNVs (data not shown).
Discussion
Here, we have profiled a series of paired schwannoma and constitutional DNA using an array covering the entire 22q. This approach is methodologically superior to loss of heterozygosity analysis (using restriction fragment length polymorphism-or microsatellite-based markers) and metaphase-CGH. One of the major advantages of array-CGH is that it allows a high-resolution comparison of tumor-derived and constitutional DNA against a reference DNA from an unrelated individual. This permits discrimination between genomic imbalances present in the constitutional DNA of the patient and tumor-specific aberrations. Previous studies reported discrepancies of 22q-associated aberrations in schwannomas, ranging from 30% to 80% (Seizinger et al. 1986; Bijlsma et al. 1992; Jacoby et al. 1996; Bruder et al. 1999b; Antinheimo et al. 2000) . The overall frequency of tumor-specific aberrations in this study was 53%. Furthermore, we did not observe any tumor presenting a pattern of multiple discontinuous deletions across chromosome 22, which has been previously described (Bruder et al. 1999b ). Several of the alterations detected in this study had common breakpoints, indicating the presence of recombination-prone, unstable genomic structures. Segmental duplications (also called low copy repeats, LCRs) are known to mediate chromosomal rearrangements during meiosis that result in altered gene dosage and are associated with e.g., velo-cardio-facial syndrome/DiGeorge-, der(22)-, and cat-eye syndromes (Zackai and Emanuel 1980; Stankiewicz and Lupski 2002; Babcock et al. 2003) . In this report we observed a clear connection between the position of breakpoints (present both in tumors and/or constitutional DNA) and the location of segmental duplications. For instance, the breakpoints of the three identified terminal deletions map to LCR-rich region of 22q11.2. Another good example is the tumor-specific interstitial deletion of schwannoma S-617 ( Fig. 1c and Table 1 ), in which the centromeric breakpoint (clone AL022332) overlapped with RCNV3, a germline deletion described in patient S-536 (Fig. 2e, f) . Bioinformatic analysis of clone AL022332 revealed a complex picture of intra-and inter-chromosomal segmental duplications that may promote the observed rearrangements (not shown). Furthermore, the centromeric breakpoint of the terminal deletion detected in schwannoma S-9 overlaps precisely with the centromeric breakpoint of RCNV1, which was amplified in constitutional DNA of patient S-475 (Table 1). Thus, in summary, the above observations support the involvement of segmental duplications in the generation of genomic rearrangements not only during meiosis, but also during mitosis.
One interesting example of a common CNV is CCNV4, which was deleted in several patients (Table 1 and Fig. 3 ) and one normal control. The known genes encompassed by this copy number variation are: Ddopachrome tautomerase (DDT) and glutathione Stransferase theta 1 and 2 (GSTT1 and GSTT2). Bioinformatic analysis of the region revealed the presence of large intra-chromosomal segmental duplications, both in direct and inverted orientation (Fig. 3) . It has been proposed that unequal crossing-over between duplicated segments directly oriented can lead to either deletion or duplication. Furthermore, recombination between Fig. 2 Identification of loci displaying CNVs in four schwannoma patients. a Array-CGH profile and the corresponding detailed view (b) of the identified regional gain (rare copy number variation, RCNV1), denoted by the box in female schwannoma case S-475. The amplified 280 kb region encompassed nine clones (D87012-D86996) mapping to the centromeric border of the IGLV locus. Two heterozygous deletions, CCNV2 and CCNV3, including clones AC008079-AC008103 and D86991-D87002, respectively, are highlighted in circles.c Array-CGH profile and the corresponding detailed view (d) of the locus within the box (rare copy number variation 2, RCNV2) in female schwannoma case S-473. The identified heterozygous deletion was 210 kb in size and encompassed six clones (D86994-D87024) on the telomeric end of the IGLV locus. The circle highlights CCNV1.e Array-CGH profile and the corresponding detailed view (f)of the highlighted locus (rare copy number variation 3, RCNV3) in female schwannoma case S-536. The detected 290 kb heterozygous deletion encompassed clones AL022332, AL0223224 and AL008721.g Array-CGH profile and the corresponding detailed view (h) of the locus (rare copy number variation 4, RCNV4) in female schwannoma case S-496. The discovered amplification was 50-75 kb in size, encompassed clones (Z82179 and Z73421) and was consistent with three gene copies. The circle highlights a heterozygous deletion of CCNV1. The general outline of the figure is the same as described for Fig. 1 Bioinformatic analysis of this region revealed the presence of intralocus segmental duplications. Three paired modules, larger than 9,000 bp and with similarity greater than 90%, are represented in black, gray and white arrows, which also indicate the relative orientation of these modules. The clones, segmental duplications and genes are drawn to scale. Genes drawn above the axis are transcribed in the positive orientation and those beneath, in the reversed direction. The scale denotes the position on the chromosome duplicated segments in inverted orientation may result in deletion or inversion (Stankiewicz and Lupski 2002) . Both scenarios are thus possible within CCNV4. The presence of CNV encompassing the GSTT1 gene has previously been reported (Garte et al. 2001) . However, to our knowledge, rearrangements mediated by segmental duplications have yet not been associated with this CNV. GSTT1 and GSTT2, located approximately 50 kb away from each other, are members of a protein superfamily responsible for detoxification of metabolites through conjugation with reduced glutathione, followed by excretion from the body. GSTT1 and GSTT2 genes have a similar genomic structure and share 55% amino acid sequence identity. Both these enzymes have been implicated in human carcinogenesis. Individuals who are carriers of homozygous deletion (null-genotype) may have an impaired ability to eliminate certain carcinogenic compounds and therefore be at increased cancer risk (Rebbeck 1997; Au et al. 2001; Garte et al. 2001 ). This aspect of our study certainly deserves a follow-up, in order to compare the frequency of different GSTT1 and GSTT2 genotypes in normal populations with various cohorts of patients affected with cancer, among them tumors of the nervous system. Our current array allows the detection of CNVs affecting the GSTT1/ GSTT2 locus and can distinguish between 0, 1, and 2 copies of these genes. However, it is not only the presence or absence of the CNV which matters, but the size of the deletion/gain must also be considered and the present platform does not allow the accurate detection of possible differences in the size of this CNV. This calls for the development of an improved version of this array, allowing an even higher resolution of analysis. In this context it is relevant to mention that the recent linkage analysis in schwannomatosis families showed the highest LOD score (6.6) to marker D22S1174, which is located in the immediate telomeric vicinity of the GSTT1 locus (MacCollin et al. 2003) . The study of human variation at the DNA level has received considerable attention in recent years. The predominant type of variation explored so far has been at the level of single nucleotide polymorphisms (SNPs). The degree to which DNA copy number variation, involving deletions and amplifications, contributes to human genetic diversity is, however, largely unknown. The comprehensive analysis of CNVs in the human genome has been complicated, mainly due to the lack of high-resolution and high-throughput techniques. A fundamental step towards identifying such variation has been the development of array-CGH (Solinas-Toldo et al. 1997; Pinkel et al. 1998; Snijders et al. 2001; Mantripragada et al. 2004 ). Recently, two landmark studies have convincingly shown the presence of genomic imbalances among a limited number of normal individuals, using different genome-wide array-CGH approaches (Iafrate et al. 2004; Sebat et al. 2004) . We identified eight different loci (four CCNV and four RCNV) across chromosome 22 that showed gain or loss of 50 to a few hundred kb. The presence of CNV may reflect the inherent instability of these genomic regions and might also play a role in determining genetic diversity and/or disease susceptibility. Analysis of 18 normal controls confirmed the presence of all CCNVs but none of the RCNVs. An assessment of larger number of normal individuals is necessary in order to associate these CNVs to schwannoma predisposition. Interestingly, only four of the eight CNV were identified in the above mentioned-genome-wide studies (Iafrate et al. 2004; Sebat et al. 2004 ). On the other hand, our study did not identify some of variation seen by Sebat et al. (2004) and Iafrate et al. (2004) , which points to the possibility that the extent of DNA copy number variation in the human genome is heavily underestimated.
